This document is a publication of a European patent application (EP3958910A1) for "Anti-CD45 antibody drug conjugates and uses thereof." The applicant is Regeneron Pharmaceuticals, Inc. The publication date is March 11, 2026. This is a notice of a patent application, not a final grant or a rule with compliance obligations.

As this is a patent application publication, there are no immediate compliance actions required for regulated entities. Companies in the pharmaceutical sector, particularly those involved in antibody-drug conjugate development, should note this publication for competitive intelligence and potential intellectual property landscape analysis. No deadlines or penalties are associated with this notice.